Novo Nordisk's 42% Volume Drop and 229th Rank as GLP-1 Market Share Wanes vs. Eli Lilly

Market Snapshot

On March 23, 2026, Novo Nordisk (NVO) closed at $36.82, reflecting a 0.79% increase from its previous close of $36.53. Despite the positive price movement, the stock’s trading volume of $0.55 billion marked a 42.83% decline compared to the prior day, ranking it 229th in trading activity. The company’s market cap stood at $164.13 billion, with a price-to-earnings (P/E) ratio of 10.43 and a forward dividend yield of 5.09%. The day’s range was $36.48 to $37.21, while the 52-week range spanned $35.85 to $81.44.

Key Drivers

The recent performance of Novo Nordisk reflects a complex interplay of competitive pressures, pipeline developments, and market dynamics. A critical factor is the intensifying competition in the GLP-1 obesity and diabetes drug market, particularly from Eli Lilly. Novo’s U.S. market share in this segment has dipped below 40%, contrasting with Lilly’s blockbuster results, including $11.7 billion in combined Mounjaro and Zepbound sales in Q4 2025. Novo’s obesity and diabetes sales grew by a modest 7% year-over-year, compared to Lilly’s 42% overall growth. This underperformance has led to investor skepticism, with the stock trading at a 11x forward earnings multiple—well below Lilly’s valuation.

A second key driver is the looming threat of generic competition. Novo has warned of potential 5% to 13% sales declines in 2026 due to patent expirations in India, Canada, Brazil, and China. In India, the company reduced Wegovy’s price by 37% ahead of patent expiry, a move analysts suggest is necessary to retain market share against generic alternatives. However, analysts remain divided on Novo’s ability to maintain its premium pricing in these markets. Sydbank analyst Søren Løntoft Hansen noted that Novo has historically retained leadership despite patent losses, citing its strong insulin market dominance and production scale.

Third, Novo’s pipeline developments have introduced both optimism and uncertainty. The company initiated a Phase 1 trial for LX9851, an oral obesity drug licensed from Lexicon Pharmaceuticals, marking a strategic push into next-gen treatments. The trial, expected to conclude in early 2027, triggered a $10 million milestone payment to Lexicon and could lead to up to $1 billion in total payments. However, the stock initially fell 1.5% following the trial announcement, reflecting market concerns about the drug’s long-term commercial viability. Novo’s leadership highlighted LX9851 as a “novel approach” to metabolic conditions, but the drug must prove superior to existing therapies like tirzepatide, where Novo’s CagriSema trial recently fell short of Phase 3 goals.

Political and pricing pressures further weigh on the stock. Novo faces U.S. pricing reductions under a November 2025 agreement with the Biden administration, which slashed GLP-1 prices. The company also navigates broader market skepticism about its ability to regain growth momentum under its new CEO. Institutional investors, including Norway’s $2 trillion sovereign-wealth fund, have abstained from re-electing Lars Rebien Sorensen as chairman, citing governance concerns over his dual role at the Novo Nordisk Foundation. Proxy adviser Institutional Shareholder Services echoed these concerns, highlighting structural power imbalances that could undermine minority shareholder interests.

Finally, the stock’s 5.09% dividend yield offers some appeal amid its valuation discount, but analysts caution that earnings recovery hinges on successful pipeline execution and market share retention. Novo’s 2026 guidance, which anticipates profit declines due to pricing pressures and generic competition, has reinforced the stock’s underperformance relative to peers. While the company’s recent partnership with Hims to boost online Wegovy sales and its expansion in India’s generic-weight-loss market present opportunities, the path to reversing its current trajectory remains uncertain. Investors will closely watch Q4 2026 results and regulatory developments for Eli Lilly’s oral GLP-1 drug, expected to gain FDA approval in Q2 2026, to gauge Novo’s ability to reclaim its market leadership.